See more : Guangdong Jushen Logistics Co., Ltd. (001202.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Tempest Therapeutics, Inc. (TPST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tempest Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jilin Electric Power Co.,Ltd. (000875.SZ) Income Statement Analysis – Financial Results
- Enterprise 4.0 Technology Acquisition Corp. (ENTF) Income Statement Analysis – Financial Results
- Brookfield Reinsurance Ltd. (BNRE.TO) Income Statement Analysis – Financial Results
- Aryan Share & Stock Brokers Lt (ARYAN.BO) Income Statement Analysis – Financial Results
- Chang Wah Electromaterials Inc. (8070.TW) Income Statement Analysis – Financial Results
Tempest Therapeutics, Inc. (TPST)
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 295.00K | 653.00K | 277.00K | 9.74M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 5.40M | 2.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -381.00K | -1.81M | -1.27M | -815.00K | -1.05M | -32.00K | 267.00K | -4.75M | -1.97M | 9.74M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 90.51% | -727.11% | -711.91% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.50M | 22.53M | 17.17M | 14.39M | 27.84M | 14.43M | 14.53M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M | 1.17M |
| General & Administrative | 11.66M | 12.11M | 9.82M | 4.91M | 5.51M | 12.45M | 27.74M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 16.50M | -3.79M | -21.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.66M | 12.11M | 9.82M | 4.91M | 16.50M | 8.66M | 5.93M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 1.45M |
| Other Expenses | 0.00 | 549.00K | -34.00K | 0.00 | 0.00 | 0.00 | 4.03M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 44.35M | 23.08M | 20.45M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M | 2.62M |
| Cost & Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 45.40M | 23.12M | 20.48M | 76.27M | 72.28M | 47.93M | 29.13M | 13.53M | 2.62M |
| Interest Income | 1.12M | 549.00K | 1.28K | 90.00K | 264.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.00K | 0.00 |
| Interest Expense | 1.45M | 1.62M | 1.28M | 0.00 | 0.00 | 134.00K | 0.00 | 659.00K | 436.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 2.24M | 1.29M | 450.00K | 231.00K | 0.00 | 0.00 |
| EBITDA | -28.78M | -32.28M | -25.72M | -18.39M | -43.52M | -27.01M | -84.27M | -79.82M | -71.86M | -49.07M | -28.81M | -13.53M | -2.62M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,933.56% | -11,236.45% | -25,528.16% | -504.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.16M | -34.64M | -26.99M | -19.30M | -45.40M | -23.12M | -20.48M | -75.61M | -72.00M | -47.93M | -29.13M | -13.53M | -2.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,943.05% | -11,579.17% | -25,992.42% | -492.38% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -334.00K | -1.07M | -1.32M | 90.00K | -21.19M | -4.06M | -64.10M | -1.05M | -1.15M | -1.59M | 90.00K | 19.00K | 0.00 |
| Income Before Tax | -29.49M | -35.71M | -28.30M | -19.21M | -44.57M | -27.18M | -84.59M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M | -2.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,673.22% | -12,566.46% | -26,405.78% | -508.68% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.07M | 1.25M | -90.00K | 1.00K | -169.00K | 67.00K | 201.00K | 75.00K | -1.59M | 90.00K | 0.00 | 0.00 |
| Net Income | -29.49M | -36.78M | -29.55M | -19.12M | -44.57M | -27.19M | -84.58M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M | -2.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,670.51% | -12,597.24% | -26,432.85% | -508.68% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| EPS Diluted | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| Weighted Avg Shares Out | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
MTSL Stock: 16 Things to Know About Penny Stock Mer Telemanagement as Shares Skyrocket
Mer Telemanagement (MTSL) stock is heading higher on Monday despite a lack of news from the company and heavy trading of shares. The post MTSL Stock: 16 Things to Know About Penny Stock Mer Telemanagement as Shares Skyrocket appeared first...
TPST Stock: 13 Things to Know About Tempest Therapeutics as Shares Skyrocket Post-Merger
Tempest Therapeutics (TPST) stock is rocketing higher on Monday and reaching new highs since its merger with Millendo Therapeutics. The post TPST Stock: 13 Things to Know About Tempest Therapeutics as Shares Skyrocket Post-Merger appeared first on InvestorPlace.
TPST Stock Increases over 120% Pre-Market: Why It Happened
The stock price of Tempest Therapeutics, Inc. (Nasdaq: TPST) increased by over 120% pre-market. This is why it happened.
TPST Stock Increases Over 76% Intraday: Details
The stock price of Tempest Therapeutics, Inc. (Nasdaq: TPST) increased by over 76% intraday. This is why it happened.
Tempest to Participate in William Blair 2021 Biotech Focus Conference
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Sam Whiting, M.D., Ph.D., chief medical officer,...
Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appointment of 20-year industry veteran Christine Pellizzari...
Source: https://incomestatements.info
Category: Stock Reports